Recent advances in cancer immunotherapy—ranging from immune-checkpoint blockade
therapy to adoptive cellular therapy and vaccines—have revolutionized cancer treatment …

The adoptive transfer of T cells that are engineered to express chimeric antigen receptors
(CARs) has shown remarkable success in treating B cell malignancies but only limited …

T cell receptors (TCRs) enable T cells to specifically recognize mutations in cancer cells,–.
Here we developed a clinical-grade approach based on CRISPR–Cas9 non-viral precision …

Many approaches to identify therapeutically relevant neoantigens couple tumor sequencing
with bioinformatic algorithms and inferred rules of tumor epitope immunogenicity. However …

T cells express T cell receptors (TCRs) composed of somatically recombined TCRα and
TCRβ chains, which mediate recognition of major histocompatibility complex (MHC)–antigen …

Neoantigens are peptides derived from non-synonymous mutations presented by human
leukocyte antigens (HLAs), which are recognized by antitumour T cells,,,,,,,,,,,,–. The large …

Cancer elimination in humans can be achieved with immunotherapy that relies on T
lymphocyte-mediated recognition of tumor antigens. Several types of these antigens have …

Public neoantigens (NeoAgs) represent an elite class of shared cancer-specific epitopes
derived from recurrently mutated driver genes. Here we describe a high-throughput platform …

Cancer is a leading cause of death worldwide and, despite new targeted therapies and
immunotherapies, many patients with advanced-stage-or high-risk cancers still die, owing to …

Mobilizing antitumour immunity through vaccination potentially constitutes a powerful
anticancer strategy but has not yet provided robust clinical benefits in large patient …